NCT03369340View on ClinicalTrials.gov

Nicotine Pharmacokinetics and Pharmacodynamics, Safety and Tolerability of P3P

NACompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

November 7, 2017

Primary Completion Date

February 1, 2018

Study Completion Date

May 2, 2018

Conditions
Pharmacokinetics
Interventions
OTHER

P3P 1

2 mg of nicotine; no flavor; nicotine powder particle size of 2.25 ± 0.2 μm

OTHER

P3P 2

2 mg of nicotine; flavor; nicotine powder particle size of 2.25 ± 0.2 μm

OTHER

P3P 3

1 mg of nicotine; flavor; nicotine powder particle size of 2.25 ± 0.2 μm

OTHER

P3P 4

2 mg of nicotine; flavor; nicotine powder particle size of 1.8 ± 0.2 μm

Trial Locations (1)

6864

CROSS Research, Arzo

All Listed Sponsors
lead

Philip Morris Products S.A.

INDUSTRY

NCT03369340 - Nicotine Pharmacokinetics and Pharmacodynamics, Safety and Tolerability of P3P | Biotech Hunter | Biotech Hunter